Abstract
Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Current Topics in Medicinal Chemistry
Title: Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Volume: 11 Issue: 21
Author(s): Chee Fei Chin, Daniel Yuan Qiang Wong, Ramasamy Jothibasu and Wee Han Ang
Affiliation:
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Abstract: Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Export Options
About this article
Cite this article as:
Fei Chin Chee, Yuan Qiang Wong Daniel, Jothibasu Ramasamy and Han Ang Wee, Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity, Current Topics in Medicinal Chemistry 2011; 11 (21) . https://dx.doi.org/10.2174/156802611798040778
DOI https://dx.doi.org/10.2174/156802611798040778 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Nanoparticles and Immune Cells
Current Pharmaceutical Design Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Magnetic Nanoparticles as Both Imaging Probes and Therapeutic Agents
Current Topics in Medicinal Chemistry Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Advancements in the Use of Platinum Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued)